Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Operating expenses:
Research and development	$ 6,914	$ 16,242	$ 28,677	$ 49,712
General and administrative	4,801	5,706	15,266	17,848
Restructuring and impairment charges	0	0	0	1,482
Total operating expenses	11,715	21,948	43,943	69,042
Loss from operations	(11,715)	(21,948)	(43,943)	(69,042)
Interest income	1,026	2,038	3,643	6,728
Other expenses	(538)	(403)	(1,187)	(1,204)
Net loss	$ (11,227)	$ (20,313)	$ (41,487)	$ (63,518)
Net loss per common share, basic (in dollars per share)	$ (1.53)	$ (2.78)	$ (5.67)	$ (8.72)
Net loss per common share, diluted (in dollars per share)	$ (1.53)	$ (2.78)	$ (5.67)	$ (8.72)
Weighted-average shares used to compute net loss per common share, basic (in shares)	7,323,106	7,296,222	7,313,329	7,286,967
Weighted-average shares used to compute net loss per common share, diluted (in shares)	7,323,106	7,296,222	7,313,329	7,286,967